Fulcrum Therapeutics

company

About

Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.

  • 101 - 250

Details

Last Funding Type
Series B
Last Funding Money Raised
$80M
Industries
Biotechnology,Genetics,Health Care,Therapeutics
Founded date
Jan 1, 2016
Number Of Employee
101 - 250
Operating Status
Active

Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.

Founded in 2016, the company is based in Cambridge, Massachusetts, United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$80M
Fulcrum Therapeutics has raised a total of $80M in funding over 2 rounds. Their latest funding was raised on Sep 5, 2018 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 5, 2018 Series B $80M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Fulcrum Therapeutics is funded by 1 investors. Sanofi are the most recent investors.
Investor Name Lead Investor Funding Round
Sanofi Series B